Thrombosis prophylaxis in myeloproliferative disorders assessed by thromboelastography
Download
1 / 17

Thrombosis Prophylaxis in Myeloproliferative Disorders Assessed by Thromboelastography - PowerPoint PPT Presentation


  • 167 Views
  • Uploaded on

Thrombosis Prophylaxis in Myeloproliferative Disorders Assessed by Thromboelastography. A. Braester, R. Nitzan-Inbar, L. Akria, A.Kuperman Institute of Hematology Western Galilee Hospital Nahariya, Israel. Thrombosis in MPD - Prophylaxis of thrombosis in MPD – ECLAP study

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Thrombosis Prophylaxis in Myeloproliferative Disorders Assessed by Thromboelastography' - kermit


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Thrombosis prophylaxis in myeloproliferative disorders assessed by thromboelastography

Thrombosis Prophylaxis in Myeloproliferative Disorders Assessed by Thromboelastography

A. Braester, R. Nitzan-Inbar, L. Akria, A.Kuperman

Institute of Hematology

Western Galilee Hospital

Nahariya, Israel


  • Thrombosis in MPD Assessed by Thromboelastography

    - Prophylaxis of thrombosis in MPD – ECLAP study

  • What is thromboelastography?

    - The efficiency of TEG to assess the need of aspirin in PV.


Thrombosis in pv et
Thrombosis in PV/ET Assessed by Thromboelastography

Thombotic complications characterize the clinical course of PV/ET and represent the main cause of morbidity and mortality.

The problem of “benefit/risk” aspirin prophylaxis.

The rationale: Platelet biosynthesis of thromboxane A2 is increased and can be suppresed by aspirin.


Mechanism of thrombosis in MPD Assessed by Thromboelastography

Age, thrombotic history and treatment

Blood hyperviscosity

High platelet count (?)

Platelet abnormalities (qualitative)

Increased thromboxane A2 production

Proliferative activity of the disease (increased production of prothrombotic cells / substances).

Thrombophilia

Cardiovascular: HT, smocking, hypercholesterol.

JAK2 V617F


  • Thrombosis in MPD Assessed by Thromboelastography

    - Prophylaxis of thrombosis in MPD – ECLAP study


European collaboration on low dose aspirin in pv eclap
European Collaboration on Low-dose Aspirin in PV Assessed by ThromboelastographyECLAP

a. Major thrombosis occurred in 3 per 100 patients/year.

b. High plt biosynthesis of thromboxane A2 can be suppressed by low-dose aspirin.

c. 518 pts enroled; follow-up 3-4 years.

d. treatment with aspirin reduced the risk of major thromboses.

e.CONCLUSION: low-dose aspirin can safetely prevent thrombotic complications in PV.


  • Thrombosis in MPD Assessed by Thromboelastography

    - Prophylaxis of thrombosis in MPD – ECLA study

  • What is thromboelastography?


TEG Assessed by Thromboelastography

Provides comprehensive clotting profile analysis as it measures initial clot formation time, time to maximum clot, clot speed, clot strength and fibrinolysis.

TEG can foresee the thrombotic potential in certain situations.


  • Thrombosis in MPD Assessed by Thromboelastography

    - Prophylaxis of thrombosis in MPD – ECLA study

  • What is thromboelastography?

    - The efficiency of TEG to assess the need of aspirin in PV.


Methods: Patients suffering from PV or ET were enrolled and a TEG analysis of the platelets was performed. Time, rate, strength and stability of the clot predicts if this clot will be able to complete a normal process of hemostasis. Maximum amplitude (MA) registered from the TEG tracing is a direct function of the platelets bonding via GP IIb/IIIa to fibrin, through platelet aggregation, clot strengthening and fibrin cross linkage. With the help of TEG we can see in all patients, including those who are on Aspirin, if this prophylaxis is warranted.


Results: We found patients on Aspirin who are resistant to this medication and are at high risk for thrombosis (MA more than upper limit of normal); we also found patients receiving Aspirin without a real need for this prophylaxis (MA normal, without a risk for thrombosis); we found patients treated with Hydrea but not with Aspirin who need prophylaxis (MA more than upper normal limit) or are not in need of prophylaxis (MA less than upper limit of normal).


Conclusions: TEG is an important test to determine the risk of thrombosis and the need for prophylaxis and to detect the patients resistant to Aspirin.


ad